# Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

> **NCT06450886** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Abcuro, Inc.** · enrollment: 270 (estimated)

## Conditions studied

- Inclusion Body Myositis (IBM)

## Interventions

- **DRUG:** Ulviprubart (ABC008)

## Key facts

- **NCT ID:** NCT06450886
- **Lead sponsor:** Abcuro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2029-01
- **Final completion:** 2029-04
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450886, "Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06450886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*